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ABSTRACT 
Objective 
To investigate the prognostic value of US in predicting musculoskeletal flares and Jaccoud’s 
arthropathy (JA) in Systemic Lupus Erythematosus (SLE). 
Methods 
Eighty out of 94 patients (76 female; age 45.5±13.2 years) with non-deforming non-erosive 
(NDNE) arthritis and 48/60 healthy controls (42 female; age 49.6±11.6 years) completed the 5-year 
follow-up study. Each patient was prospectively assessed for the occurrence of musculoskeletal 
flares using BILAG2004 and hand deformities according to Jaccoud’s articular index. Baseline 
clinical, serological, semi-quantitative (0 – 3 scale) ultrasound (US) findings, PD-synovitis and PD-
tenosynovitis scores were used as covariates to identify predictors of study outcomes. Short Form 
36 v2 (SF36v2) health survey questionnaire was administered. 
Results 
Twelve MS flares in 10 (12.5%) patients were recorded and the incidence rate was 3.0 per 
100 patient-year. Baseline PD-synovitis score independently predicted MS flare (p<0.001; RR 2.0; 
95% CI 1.4 – 3.0) within 2 years since US examination. Five (6.2%) patients developed JA whose 
incidence rate was 1.25 per 100 patient-year. Independent risk factors for development of JA were 
higher longitudinal BILAG score in the musculoskeletal domain (p=0.005; RR 2.4 95% CI 1.3 - 
4.6) and longer disease duration (p=0.013; RR 1.2; 95% CI 1.1-1.3). JA and active musculoskeletal 
inflammation (BILAG≥C), but not US erosions, were associated with lower results in SF36v2 
physical and mental summary components. 
Conclusions 
3 
Performing musculoskeletal US can be useful in order to predict MS flares. Jaccoud’s 
deformities may arise in patients with long-standing SLE and prolonged, even subclinical, joint and 
tendon inflammation. 
 
 
KEYWORDS: Systemic Lupus Erythematosus, high-resolution ultrasound, musculoskeletal 
disorders, Jaccoud’s arthropathy, health related quality of life, prospective study. 
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1. Introduction 
Musculoskeletal (MS) complaints are very common in Systemic Lupus Erythematosus 
(SLE) affecting 70-95% of patients (1-3). They represent the heralding symptom in 60-80% of 
cases and are reported in up to 60% of disease flares (3, 4). Inflammatory MS manifestations are 
described as a major cause of pain and compromised hand function, interfering with daily activities 
in 73% of SLE patients and causing low productivity or work disability in 49% and 17% of them, 
respectively (5-8). In particular, impairment of patients' health related quality of life (HRQoL) is 
mostly associated with MS flares (9, 10). Inflammatory joint involvement in SLE primarily affects 
the hands and clinically occurs as transient and migratory arthralgia (30-50%), or fleeting (25-40%) 
or persistent (10-15%) arthritis but tenosynovitis could also be present (11). SLE arthritis is often 
classified as non-deforming and non-erosive (NDNE) on X-ray (12), but hands and feet deformities 
may arise in 5-15% of cases as hallmarks of Jaccoud’s Arthropathy (JA) (12, 13). Radiographic 
erosions may be detected in less than 5% of patients showing persistent arthritis, sometimes 
deformities, high prevalence of rheumatoid factor (RF) and anti-cyclic citrullinated peptide 
antibodies (aCCP), thus referred as rhupus syndrome (RS) to indicate an overlap between 
Rheumatoid Arthritis (RA) and SLE (12, 14). This classification has been recently questioned by 
ultrasound (US) studies that showed an unexpected burden of erosive damage in up to 41% of 
patients as well as a surprisingly high prevalence of synovitis (25-94%) and tenosynovitis (28-65%) 
(15)..  
These data challenge the belief that lupus arthritis is a benign entity and suggest that the 
burden of joint damage in SLE may be underestimated (15, 16), Identifying factors associated with 
MS flares and development of joint damage, such as deformities, would help preventing a major 
cause of disability for SLE patients. In particular, unveiling the progression and predictive values of 
synovitis, tenosynovitis and erosions detected by high-resolution US, which prognostic properties 
have not been addressed by longitudinal studies, can be crucial in facilitating targeted therapies and 
measuring response (15, 16). US was proved to be more sensitive than clinical examination in 
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detecting joint ad tendon inflammation (17-21), which even subclinical has been reported as 
predictive of MS flare (22) and responsible for future development of JA (23). This prospective 
study was planned with the aim to clarify whether and which high-resolution US findings are 
associated with an increased risk of MS flares and JA. As secondary aims we would estimate their 
prevalence and incidence, highlighting their impact on patients HRQoL and identifying other 
relevant clinical or serological predictive factors. 
 
2. Patients and methods 
 
2.1. Study design  
Ninety-four consecutive Caucasian patients fulfilling at least 4 of the 1997 ACR criteria for 
SLE (24) were recruited between January 2010 and April 2010 in a 5-year prospective study. 
Follow-up visits were scheduled every 6 months (figure 1). In order to assure complete capturing of 
clinically significant data, patients were asked to refer to the clinic in case of symptoms suggestive 
of disease flare or drug adverse event and both patients and healthy controls were solicited by phone 
call to attend the scheduled visits. Those who failed to attend the scheduled visits were excluded 
from the study in order to minimize data loss. 
Inclusion criteria were: a) past or present joint and/or tendons inflammatory involvement, b) 
having not taken NSAIDs in the 5 days prior to baseline, c) having been on stable corticosteroids 
dose over previous 4 weeks, d) having been on stable antimalarial and immunosuppressive therapy 
over previous 3 months. Exclusion criteria were: i) RS defined by the presence of X-ray erosions or 
fulfilment of both SLE and RA classification criteria (25), ii) hand and feet deformities, iii) 
avascular necrosis or iv) myositis. Sixty age- and gender-matched volunteers were recruited from 
healthy hospital staff as controls.  
Ethical approval for the study was obtained from the local Ethics Committee (references 
111/10/CE and 224/11/CE) and all participants gave their written informed consent. 
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2.2.Study outcomes 
The British Isles Lupus Assessment Group (BILAG) 2004 disease activity index is sensitive 
to change and suitable for use in longitudinal studies of SLE if the outcome of interest is worsening 
of disease activity (26). MS flares were defined as any increase in activity to grade A (severe) or B 
(moderate) in the MS-BILAG domain. Any increase in activity to grade C was defined as minimal 
change and not included in flare definition (26). 
Development of JA was defined as any increase (≥1) in JA index (table 1) calculated 
according to Spronk et al. (23). 
 
2.3.Clinical assessment  
At every visits, patients and controls underwent detailed standardized joints and tendons 
examination according to EULAR recommendations (27). A bilateral examination for tenderness 
and swelling of the following joints was performed: shoulder, elbow, wrist, metacarpophalangeal 
(MCP) , proximal inter-phalangeal (PIP) of the hand, knee, ankle and metatarsophalangeal (MTP). 
Fixed or reducible MCP subluxation, ulnar drift, swan neck or boutonniere deformities of the 
fingers and Z thumbs were also evaluated. A bilateral examination for tenderness and swelling of 
the following tendons or group of tendons was performed: flexor pollicis longus tendon, flexor 
carpi radialis tendon, flexor digitorum tendons of the second, third, fourth and fifth fingers (at both 
common tendon sheath and finger tendon sheath level), extensor tendons of the first, second, third, 
fourth, fifth, and sixth compartments.  
SLEDAI was used to assess global disease activity and BILAG was applied to evaluate 
disease activity in individual organ systems. A mean longitudinal MS-BILAG score was calculated 
by assigning at each visit result an additive numerical scoring scheme as follows: A = 12 (very 
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active disease), B = 8 (moderate activity), C = 1 (mild stable disease) and D = 0 (inactive but 
previously involved) (28). According to inclusion criteria no patient scored E (no current or 
previous disease activity). Cumulative organ damage was calculated using the ACR/Systemic 
Lupus International Collaborating Clinics Damage Index (SDI). 
Medications ongoing at baseline, classified as immunosuppressant, antimalarial, low dose 
prednisone (<10 mg daily or equivalent) or high dose prednisone (≥10 mg daily or equivalent) were 
categorized as present/absent. Modifications of treatment, defined as increased (introduction of new 
agent or increased dose) or lowered (withdrawal or dose reduction) immunosuppressive, 
antimalarial or corticosteroids therapy, were recorded. The scheduled switch from induction (i.e. 
cyclophosphamide or mycophenolate) to maintenance therapy (i.e. azathioprine or other 
immunosuppressant) in management of renal or central nervous system involvement were not 
considered as modifications of treatment.  
At the end of follow-up, the Short Form 36 v2 (SF36v2) health survey questionnaire was 
administered to assess HRQoL. 
Clinical assessment and indices calculation were performed by a trained rheumatologist 
blind to serologic, ultrasonographic and radiologic findings. 
 
2.4.Serologic assessment 
At baseline, each patient was tested for ANAs (IF Hep-2), anti-Ro/SSA, anti-La/SSB, anti-
RNP, anti-Sm (ELISA; Normal Value (NV) <10 IU/dl), RF (ELISA; NV<14 IU/dl) anti-CCP 
(ELISA; NV<25 IU/dl) and HLA-DR1/DR4 status. Anti-dsDNA (Farr assay; NV<7 IU/dl), CRP 
(NV<0.5 mg/dl), C3 (NV 90-180 mg/dl) and C4 (NV 10-40 mg/dl) complement fraction levels was 
tested at baseline and prior to each follow-up visit.  
 
2.5.Ultrasound and radiographic assessment 
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Patients (baseline, flare-up and final visits) and healthy controls (baseline and final visits) 
underwent the same high-resolution US examination protocol performed by an experienced 
rheumatologist, blind to clinical data, using a Logiq9 (GE, Medical Systems, Wisconsin, USA) with 
an 8-15 MHz linear array probe. On the basis of previous studies that identified the most frequently 
affected joints and tendons in SLE (18-20, 29) the following anatomic sites were bilaterally 
evaluated using a multi-planar scanning technique: second and third MCP and wrist joints, flexor 
pollicis longus tendon, flexor carpi radialis tendon, flexor digitorum superficialis and profundus 
tendons of the 2
nd
 to the 5
th
 fingers (at both carpal tunnel and finger levels) and extensor tendons of 
the 1
st
 to the 6
th
 compartments at the dorsal aspect of the wrist. All the tendon or group of tendons 
surrounded by a single tendon sheath, were scanned in transverse view from the most proximal to 
the most distal portion at the tracts surrounded by synovial sheath. All findings were also 
documented in the corresponding perpendicular longitudinal view. Values of grey-scale (GS) 
setting parameters were fixed before the study to obtain maximal contrast of different soft tissues 
examined. Power-Doppler (PD) settings were adjusted according to Torp-Pedersen’s 
recommendations (30). Bone erosion, tenosynovitis and synovitis were scored as present/absent 
according to OMERACT definitions  (31). GS-tenosynovitis and GS-synovitis as well as PD-
tenosynovitis and PD-synovitis (figure 2) were further semi-quantitatively graded from 0 to 3 
(0=normal; 1=mild; 2=moderate; 3=severe) as described elsewhere (31-33). PD-synovitis (range 0-
18) and PD-tenosynovitis (range 0- 74) scores were the sum of the grades of all PD signal on the 
targeted joints and tendons, respectively.  
Inter-observer agreement rates (k values) with another sonographer was evaluated in half of 
patients and healthy controls and resulted good-to-excellent for qualitative assessment (0.68 - 0.96), 
for GS-synovitis (0.71 – 0.93), GS-tenosynovitis (0.64 – 0.83), PD-synovitis (0.76 – 0.84) and PD-
tenosynovitis (0.78 – 0.91) semi-quantitative assessment. Patients underwent plain radiography of 
the hands and wrists at baseline and final assessment with the aim to identify any erosive pattern 
related to inflammatory arthritis in this cohort. An expert rheumatologist, blind to clinical and US 
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results, evaluated X-ray looking for presence/absence of  erosions defined as breaks in the cortical 
bone surface with or without new bone formation. 
2.6.Statistical analysis 
The characteristics of interest were reported as mean ± standard deviation (S.D.) or median 
(25
th
 - 75th percentiles) for normal or non-normal distributed variables, according to Kolmogorov-
Smirnov test, and number with corresponding percentage.  
The search for independent predictive factors of MS flares (present/absent at any time point) 
and JA (present/absent at the end of follow-up) included univariate analyses and stepwise Cox 
proportional hazard models. Explanatory baseline variables tested were: age, disease duration, CRP, 
positivity for anti-Ro/SSA, anti-La/SSB, anti-RNP, anti-Sm, RF, anti-CCP, C3, C4, anti-dsDNA, 
SLEDAI, SDI, MS-BILAG score, ongoing medication, US erosions, GS-synovitis ≥2, GS-
tenosynovitis≥2, PD-synovitis≥1, PD-tenosynovitis≥1, PD-synovitis score, PD-tenosynovitis score. 
Considering the long observation time, in order to minimize any possible bias effect, we included 
longitudinal MS-BILAG score, occurrence and number of MS flare (only for JA as outcome), and 
modifications of treatment with antimalarial, immunosuppressant, corticosteroids as time-varying 
explanatory variables. For same reason, the time-varying effect of US baseline findings in 
predicting MS flare at each year of follow-up was tested. Student’s t-test, or Mann-Whitney test if 
necessary, and Chi-square test were used for quantitative and qualitative variables, respectively. 
Stepwise Cox proportional hazard models were fitted with covariates with p<0.1 to predict 
outcomes. Specificity and sensitivity of predictive factors was calculated by mean of ROC curve. 
Two-tailed p values less than 0.05 were considered significant. Relative Risk (RR) with 95% 
Confidence Interval (CI) were calculated. Statistical analyses were performed using the software 
package MedCalc 15.0 (MedCalc Software, Mariakerke, Belgium).  
 
3. Results 
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3.1 Study population 
Eighty patients (76 female; age 45.5±13.2 years) and 48 healthy controls (42 female; age 
49.6±11.6 years) completed the 5-year follow-up (Table 2). Reasons for drop-out of 14 SLE 
patients and 12 healthy controls were: outmigration, change of address or phone number, 
withdrawal of consent and death. No major differences between groups were detected. 
At baseline, 9/80 (11.2%) patients reported arthritis in the past month but only 7/80 (8.7%) 
had swollen joints (median count 0; range 0 - 10) at clinical examination, 19/80 (23.7%) 
complained of inflammatory arthralgia in the past month but only 10/80 (12.5%) of them had tender 
joints (median count 0; range 0 -22) at the time of visit. Six/80 (7.5%) patients had tenderness along 
the path of a tendon or group of tendons (median 0; range 0 -3) but none of them had swelling. In 
order to score for MS-BILAG, MS manifestations occurred in the 4 weeks prior to baseline were 
compared with those of the 4 weeks before resulting in 1/80 (1.3%) patients scoring A on MS-
BILAG, 6/80 (7.5%) scoring B, 21/80 (26.2%) scoring C and 52/80 (65.0%) scoring D. The overall 
disease activity according to SLEDAI score was 3.2±2.1, thus representative of longstanding 
Caucasian SLE cohorts according to Urowitz et al. (34) and only in a small part related to joint 
activity. 
US detected a higher number of inflamed joints and tendons than clinical examination 
(supplementary file 1). US synovitis and tenosynovitis with GS≥2 and PD≥1 were more frequent in 
patients with higher MS-BILAG score, but were also detected in 5 out of 21 (23.8%) patients 
scoring C and were almost absent (1.9%) in those scoring D (Table 3). In particular, GS-synovitis≥2 
was found in 25 (5.2%) out of 480 scanned joints (10 were not clinically tender or swollen) from 
6/80 (7.5%) patients of whom 3 scored C on MS-BILAG. PD-synovitis≥1 was detected in 32/480 
(6.7%) joints (11 without clinical synovitis), from 10/80 (12.5%) patients of whom 4 scored C on 
MS-BILAG. GS-tenosynovitis≥2 was found in 10 (0.5%) out of 1920 scanned tendon sites (8 were 
not clinically tender nor swollen) from 4/80 (5.0%) patients of whom 3 scored C on MS-BILAG. 
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PD-tenosynovitis≥1 was detected in 19/1920 (1.0%) tendon sites (13 with no sign of tenosynovitis) 
from 9/80 (11.2%) patients of whom 5 scored C and 1 scored D on MS-BILAG.  
Considering US as the gold standard for joints and tendons assessment, a low sensitivity 
(31.6% for tendons, 65.6% for joints) with high specificity (96.7% for joints, 99.0% for tendons) of 
the clinical assessment was found. 
3.2 Musculoskeletal flares at patient level 
During follow-up in 3 (0.4%) out of 855 visits a MS-BILAG score of A was recorded, in 
20/855 (2.3%) it was B, in 108/855 (12.6%) it was C and in 724/855 (84.7%) it was D, confirming 
that disease activity in this cohort was only in a small part related to the joint. The distribution of 
longitudinal mean MS-BILAG score was highly skewed (median 0; IR 0 – 0.22; 95% CI 0 – 0.65).  
Twelve/855 (1.4%) MS flares (3 A severe and 9 B moderate) in 10/80 (12.5%) patients 
(median 0; range 0 - 2) and 40/855 (4.6%) minimal change in activity (any increase to C) in 31/80 
(38.8%) patients were recorded with complete capturing of clinically significant flares in patients 
included in the analysis. Mean time to MS flare occurrence was 29.0±19.0 months and annual 
incidence rate was 3.0 per 100 patient-year. Among patients who developed MS flare, 2/10 (20.0%) 
scored B at baseline, 4/10 (40%) C and 4/10 (40%) D on MS-BILAG (figure 3). Flares isolated to 
the musculoskeletal domain occurred in 4 (33.3%) cases. Major reasons for introduction of new 
medication or increased dose of ongoing treatment in 17/80 patients (21.2%) were flares, while for 
drug withdrawal or reduced dose in 29/80 patients (36.2%) were adverse events (n=12; 15.0%) and 
scheduled steroids tapering (n=20; 25.0%). 
On univariate analysis, CRP higher than upper normal limit (70.0% vs 24.3%; p=0.003), 
GS-synovitis≥2 (50.0% vs 1.4%; p<0.001), GS-tenosynovitis≥2 (20% vs 2.8%; p=0.020), PD-
synovitis≥1 (50% vs 7.1%; p<0.001), PD-tenosynovitis≥1 (60.0% vs 4.3%; p<0.001) and PD-
synovitis score [1 (0 - 4) vs 0 (0 -0); p<0.001; (figure 4A)] registered at baseline were associated 
with development of MS flare. When all US findings were entered in the multivariate model, after 
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adjusting for baseline and time varying explanatory variables, baseline PD-synovitis score resulted 
the only independent predictors (p<0.001; RR 2.0; 95%CI 1.4 – 3.0) of MS-flares within 24 months 
since US examination . Baseline PD-synovitis score >2 was associated with a 2-year risk of MS 
flare with a sensitivity of 66.7% and a specificity of 97.3% (AUC=0.804; 95% CI 0.699 – 0.886) 
(Figure 4B). 
 
3.3 Musculoskeletal flares at joint level 
At the time of MS flare, tender joint count was 7.7 (±4.4) and swollen joint count was 5.5 
(±3.0). MCP were involved in 11 out of 12 (91.7%) flares (9 bilaterally, 2 unilaterally) and in the 
only case without inflamed MCP there was PIP, wrists and elbows involvement. The PIP showed 
inflammatory signs (swelling or tenderness) in 6/12 (50.0%) cases, wrist in 4/12 (33.3%), elbow, 
knee, ankle, and MTP in 1/12 (8.3%). Three/10 patients (33.3%) in 5/12 flares (41.6%) showed a 
clinically relevant tendonitis of the finger flexor tendons. US showed PD-synovitis≥1 in 12/12 
flares (100%) and PD-tenosynovitis≥1 in 8/12 (66.7%) (see supplementary file 2).  
Forty-four (9.2%) out of 480 joints scanned by US examination at baseline showed swelling 
and/or tenderness during flare; 20/44 (45.4%) flared joint and 5/436 (1.1%) non-flared joints had 
baseline GS-synovitis≥2 (p<0.001) whereas 24/44 (54.5%) flared joints and 8/436 (1.8%) non-
flared joints (p<0.001) showed baseline PD-synovitis≥1.  
Baseline detection of US erosions was not associated with increased risk of MS-flare either 
at patient level nor at joint level. 
 
3.4 Hand deformities 
Five (6.2%) patients developed hand deformities (Table 4). The estimated incidence rate of 
JA was 1.25 per 100 patient-year. On univariate analysis longer disease duration (25.9±10.4 vs. 
13 
14.2±6.3 years; p<0.001) and CRP higher than upper normal limit (80% vs. 26.1%; p=0.026) at 
baseline or having suffered from MS flares (40.0% vs 10.7%; p=0.014), lack of immunosuppressive 
treatment (100% vs 22%; p<0.001) and higher longitudinal MS-BILAG score [0.1 (0 – 1.8) vs 0 (0 
– 0.3); p=0.001] during follow-up were associated with development of hand deformities. However, 
after adjusting for baseline and time varying confounding factors, only longer disease duration 
(p=0.013; RR 1.2; 95%CI 1.1-1.3) and higher longitudinal MS-BILAG (p=0.005; RR 2.4 95%CI 
1.3 - 4.6) were retained in the multivariate model as predictors of hand deformities. None of the 
baseline US abnormalities, including joint erosions, was associated with development of 
deformities.  
 
3.5 US erosions 
At final visit, new US erosions were revealed in 13/80 (16.3%) patients of whom 4 had US 
erosions at baseline, but none showed erosion on X-ray. Major accrual of US erosions was detected 
at second MCP level bilaterally (see supplementary file 3). The incidence of new US erosions was 
significantly higher (p=0.022) in SLE patients compared with healthy controls (n=1; 2.0%).  
 
3.6 Patient Reported Outcomes 
Patients who developed JA had worse results in both physical and mental health components 
of the SF36v2 than NDNE, and both scored worse than healthy controls (figure 5A), at the end of 
follow-up. In NDNE patients, SF36v2 mental and physical domains were mostly influenced by high 
MS-BILAG score (figure 5B) rather than by the evidence of US joint erosions (figure 5C). In 
particular, patients who scored ≥ C on MS-BILAG had statistically significant lower results in 
bodily pain (p=0.004) and global health (p=0.019) components of the SF36v2 questionnaire than 
patients who scored D. 
 
4. Discussion 
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This study identified a risk profile for musculoskeletal flares and Jaccoud’s deformities, 
reported the incidence of these two complications and depicted them as determinants of impaired 
HRQoL in a large prospectively followed-up and representative cohort of SLE patients with NDNE 
arthritis. Moreover, it provided valuable insights into the progression and predictive value of 
abnormalities detected by high-resolution US in SLE and supported previous observations 
highlighting that US is more accurate than physical examination in detecting joint and tendon 
inflammation in symptomatic SLE patients without clinical joint swelling or tendonitis (17-21).  
We firstly demonstrated that, although frequently detected in patients, baseline subclinical 
synovitis or tenosynovitis (GS=1  without PD signal) are also observed in healthy controls and had 
no prognostic or predictive value. However, the most significant and innovative finding to emerge 
from this study is that, after correction for the potential confounding effect of disease activity and 
treatment changes, a higher PD-synovitis score at baseline was independently predictive of MS flare 
within 24 months since US examination. The time-restricted effect of PD-synovitis score suggests 
that, rather than be a marker for a more aggressive (e.g. deforming) subtype of SLE arthritis, it 
recognized patients with residual or subclinical disease activity not detectable on clinical 
examination and, if not properly treated, at risk for flare. Therefore, this marker can help the 
clinician in the decision making process for starting or enhancing immunosuppressive therapy in 
order to prevent MS flare. In this scenario, performing US could be useful in clinical practice for 
symptomatic patients without synovitis on physical examination, scoring C on MS-BILAG, who do 
not deserve increased immunosuppression for high disease activity in other organs or systems. 
Along with this novel observation, we longitudinally estimated the incidence and prevalence 
of JA as 1.2 per 100 patient-year and 6.2%, respectively. To the best of our knowledge this is the 
first report on the incidence of JA in SLE patients, whereas previous cross-sectional study reported 
the prevalence of Jaccoud’s deformities as 3.5-13.3% (13, 35). The risk profile for development of 
JA was characterized by prolonged even subclinical joint and tendon inflammation, according to 
longitudinal MS-BILAG activity score, and longer disease duration. Baseline US findings were not 
15 
associated with development of JA probably because the long time needed for appearance of 
deformities and the transient nature of joint and tendon inflammation; the latter is supported by the 
relatively low incidence and severity of inflammatory abnormalities detected by US (18) and 
histopathology (36) in these patients. Subclinical inflammation in joints and tendons was addressed 
as responsible for accrual of soft tissue damage resulting in JA (36, 37), however it cannot 
satisfactorily explain why only a relatively small proportion of patients develops deformities. 
Previous cross-sectional studies (13, 18, 23, 35) identified longer disease duration as a risk factors 
for JA, but the mechanisms underlying this association are unclear. Higher cumulative dose of 
corticosteroids may be partly responsible for impaired soft tissue healing and remodeling in 
susceptible individuals (38, 39) resulting in joint laxity and loss of articular stabilizing mechanisms. 
Although we did not look at cumulative steroids dose in our cohort, patients developing Jaccoud’s 
deformities were all treated with long-standing low dose steroids and lack in immunosuppressants. 
In light of these observations we would suggest to consider JA as a late complication of NDNE, 
consequent to treatment failure, and not a distinct subtype of SLE arthritis. Further prospective 
studies are needed to evaluate the potential effect of targeted strategies, based on ultrasonographic 
tight control of MS disease activity and steroid-sparing agents, in preventing development of hand 
deformities.  
We also showed that the burden of US erosions slightly progressed over time in patients 
with NDNE but, unlike erosions seen in RA (40), they were not predictive of deformities or accrual 
of erosive damage. Moreover, it is noteworthy that US erosions were not a cause of worse HRQoL 
in NDNE patients whereas active MS activity and Jaccoud’s deformities resulted major 
determinants for low HRQoL. In the light of this evidence a patient should not be classified as 
suffering from RS relying solely on isolated US findings. In the absence of X-rays erosions, RA-
like synovitis and persistently high anti-CCP and RF should raise suspicion of pre-radiographic 
form of RS and must suggest a more aggressive treatment (41).  
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This study have some limitations. First, although we made an effort in order to minimize the 
effect of treatment confounding factors, further studies based on targeted therapy in naïve patients 
are needed to confirm these data. Nevertheless, this could be particularly difficult as lupus is a 
systemic disease and patients need different therapeutic approaches tailored according to severity of 
symptoms and occurrence of life-threatening manifestations. Second, this study was not specifically 
designed to assess the effect of different MS manifestation on HRQoL, thus our results should be 
confirmed by future studies. Third, we recorded a 14.8% and 20.0% drop-out rate in SLE patients 
and healthy controls, respectively. However, in observational studies conducted over a lengthy 
period of time a high drop-out rate is to be expected and, conventionally, a 20% drop-out rate is 
regarded as acceptable (42). Moreover, drop-out rates were comparable in the two groups and by 
assuring the complete capturing of clinically significant data we minimized concerns in 
interpretation of study results. 
In conclusion, high-resolution US could be an effective response to the unmet need for a 
more sensitive and specific tool for assessing joint and tendons in SLE patients, especially those 
scoring C on MS-BILAG complaining of inflammatory joint pain but without clinical synovitis or 
tenosynovitis. US could be clinically useful in order to identify those patients at risk for MS flare 
and consequently institute the most appropriate treatment to prevent hand deformities and 
deterioration of HRQoL. Further studies combining histopathology and imaging tools, including CT 
and MRI, are needed to shed some light on their potential clinical implications and therapeutic 
targets for preventing MS inflammation and damage in SLE patients.  
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Table 1. Description of the Jaccoud’s articular index according to Spronk et al (23). 
 
 
Jaccoud’s articular index 
Deformities Number of affected index Assigned points 
MCP subluxation with limited extension  1-4 1 
 5-8 2 
Ulnar drift (>20°) 1-4 2 
 5-8 3 
Swan neck deformities 1-4 2 
 5-8 3 
Boutonniere deformities 1-4 2 
 5-8 3 
Z-thumb deformity 1 2 
 2 3 
 
MCP: metacarpophalangeal 
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Table 2. Baseline demographic, clinical and serological feature of the 80 patients who 
completed the follow-up. 
Age at onset (years) 30.7 (±11.6) 
Disease duration at enrollment (years) 10.5 (±7.1) 
Follow-up (months) 56.6 (±6.7) 
Cumulative 1997 ACR criteria  
  Malar rash 27 (33.8) 
  Discoid rash 7 (8.8) 
  Photosensitivity 17 (21.3) 
  Oral/nasopharyngeal ulcers 10 (12.5) 
  Non-erosive arthritis 80 (100) 
  Pleuritis or pericarditis 30 (37.5) 
  Renal disorders 23 (28.8) 
  Neurologic disorders 3 (3.8) 
Laboratory findings  
  C-reactive protein 24 (30.0) 
  Low C3 Complement 36 (45) 
  Low C4 Complement 28 (35) 
  ANA  80 (100) 
  Anti-dsDNA 34 (42.5) 
  Anti-Ro/SSA 28 (35.0) 
  Anti-La/SSB 9 (11.2) 
  Anti-RNP 16 (20.0) 
  Anti-Sm 9 (11.2) 
  Rheumatoid Factor 11 (13.7) 
  Anti-CCP 4 (5.0) 
HLA-DR1 or DR4 29 (36.2) 
SLEDAI 3 (±2.1) 
SLICC/Damage Index 0.9 (±1.4) 
Ongoing Medication 80 (100%) 
  Prednisone >10mg/day 13 (16.3) 
  Prednisone<10mg/day 53 (66.3) 
  Antimalarial agents 56 (70.0) 
  Immunosuppressant 54 (67.4) 
Methotrexate 23 (28.8) 
Azathioprine 22 (27.5) 
Cyclophoshamide 2 (2.5) 
Mycophenolate Mophetil 11 (13.8) 
Rituximab 2 (2.5) 
Quantitative variables are expressed as mean ± standard deviation. Values are the number of 
patients, values in brackets are percentage. MS-BILAG: musculoskeletal domain of BILG2004. 
ANA: antinuclear antibodies (tested by IIF, using Hep2 cell substrate, positivity was defined as a 
titre ≥ 1:320).Anti-dsDNA antibodies  (tested by Farr assay ). Anti-extractable nuclear antigens 
(SSA, SSB, Sm, RNP), Rheumatoid Factor, antiCCP (anti-cyclic citrullinated peptide antibodies) 
tested by ELISA.  
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Table 3. Distribution of baseline ultrasound findings in healthy controls and in patients according to 
categorical musculoskeletal BILAG score. 
Unless otherwise indicated values are the number of patients, values in brackets are 
percentage. 
a: values are median (range) GS: gray-scale. PD: power-Doppler. 
  
Baseline US findings 
Healthy controls 
(n=48) 
SLE 
(n=80) 
BILAG A/B 
(n=7) 
BILAG C 
(n=21) 
BILAG D 
(n=52) 
GS-synovitis = 0 45 (93.7) 65 (81.2) 1 (14.3) 16 (76.2) 48 (92.3) 
GS-synovitis = 1 3 (6.3) 9 (11.2) 3 (42.8) 2 (9.5) 4 (7.7) 
GS-synovitis = 2 0 3 (3.8) 1 (14.3) 2 (9.5) 0  
GS-synovitis= 3 0 3 (3.8) 2 (28.6) 1 (4.8) 0 
PD-synovitis = 0 48 (100) 70 (87.4) 1 (14.3) 17 (81.0) 52 (100) 
PD-synovitis = 1 0 5 (6.3) 3 (42.8) 2 (9.5) 0 
PD-synovitis = 2 0 5 (6.3) 3 (42.8) 2 (9.5) 0 
PD-synovitis = 3 0 0 0  0 0 
PD-synovitis score
a
 (range 0-18) 0 0 (0 – 8) 1 (0 – 8) 0 (0 – 4) 0 (0 – 0) 
GS-tenosynovitis = 0 43 (89.6) 50 (62.5) 2 (28.6) 10 (47.6) 38 (73.1) 
GS-tenosynovitis = 1 5 (10.4) 26 (32.5) 4 (57.1) 8 (38.1) 14 (26.9) 
GS-tenosynovitis = 2 0 4 (5.0) 1 (14.3) 3 (14.3) 0 
GS-tenosynovitis= 3 0 0 0  0 0 
PD-tenosynovitis = 0 48 (100) 71 (88.7) 4 (57.1) 16 (76.2) 51 (98.1) 
PD-tenosynovitis = 1 0 4 (5.0) 0  3 (14.3) 1 (1.9) 
PD-tenosynovitis = 2 0 5 (6.3) 3 (42.8) 2 (9.5) 0 
PD-tenosynovitis = 3 0 0 0  0 0 
PD-tenosynovitis score
a
 (range 0-
78) 
0 
0 (0 – 8) 
0 (0 - 8) 
0 (0 – 4) 0 (0 – 1) 
Bone erosions 2 (4.1) 13 (16.2) 1 (14.3) 3 (14.3) 9 (17.3) 
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Table 4. Characteristics of patients who developed deformity during follow-up.  
 
a: other than arthritis. APS: antiphospholipid syndrome. JAI: Jaccoud’s articular index. HCQ: 
Hydroxychloroquine. PDN: prednisone. MCP: metacarpophalangeal. GS-S: grey-scale synovitis. 
GS-T: grey-scale tenosynovitis. PD-S: power-Doppler synovitis. PD-T: power-Doppler 
tenosynovitis 
ANA: antinuclear antibodies (tested by IIF, using Hep2 cell substrate, positivity was defined as a 
titre ≥ 1:320). Anti-dsDNA antibodies  (tested by Farr assay ). CRP: c-reactive protein.  
 
 
 
 
 
  
Age 
(Gender) 
Disease 
Duration 
Main clinical 
manifestations
a 
Serologic 
findings 
Baseline   
MS-
BILAG 
Baseline US 
findings 
Treatment 
Number 
of MS-
Flare 
JAI 
deformities 
JAI 
score 
42 yrs (F) 14 yrs 
Malar rash, 
photosensitivity
, serositis, TVP 
in APS. 
ANA, 
CRP. 
C 
GS-S=2, PD-
S=1  GS-T=2, 
PD-T=1 
HCQ, 
PDN 
2 
MCP sub-
luxation, 
swan neck 
deformities, 
Z thumbs. 
8 
57 yrs (F) 15 yrs 
Lupus nephritis, 
leukopenia, 
lymphopenia. 
ANA, 
anti-
dsDNA. 
D 
GS-S=1, GS-
T=1. 
HCQ 0 Ulnar drift 3 
57 yrs (F) 31 yrs 
Lupus nephritis, 
serositis, stroke 
in APS 
ANA, 
SSA, 
RNP, 
CRP. 
D Erosions. 
HCQ, 
PDN 
0 
Ulnar drift, 
MCP sub-
luxation, 
boutonniere 
deformities,  
5 
69 yrs (F) 36 yrs 
Discoid rash, 
leukopenia, 
lymphopenia. 
ANA, 
anti-
dsDNA, 
CRP. 
D Erosions 
HCQ, 
PDN 
1 
Ulnar drift, 
swan neck 
deformities. 
4 
65 yrs (F) 32 yrs 
Serositis, 
leukopenia, 
lymphopenia. 
ANA, 
SSA, 
CRP. 
C GS-T=1. 
HCQ, 
PDN 
0 
Ulnar Drift, 
MCP sub-
luxation. 
5 
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Figure legends  
 
Figure 1. Study design overview. 
 
Figure 2. (A) Baseline longitudinal dorsal scan of a second MCP joint, in a patient scoring 
B on MS-BILAG, showing grade 2 grey-scale synovitis (*) with (B) grade 2 power-Doppler signal 
(arrow). (C) Longitudinal volar scan of the third digit flexor tendon (t), during a severe flare, 
showing grade 2 grey-scale tenosynovitis (*) with (D) grade 2 power-Doppler signal (arrow). m: 
metacarpal head. pp: proximal phalanx. 
 
Figure 3. Distribution of MS flare over the 5-year follow-up period according to baseline 
MS-BILAG score and baseline PD-synovitis score >2 (black) or ≤2 (dark grey). 
 
Figure 4. (A) Box and whisker graph showing different distribution of baseline PD-
synovitis score in patients who and who not developed flares during follow-up. (B) Receiver 
operating characteristic curve showing association of baseline PD-synovitis score and development 
of MS flare within 2 years since US examination. 
 
Figure 5. (A) Spider plot resuming how each component of the SF36v2 varies in healthy 
controls and in patients with NDNE or Jaccoud’s arthritis. Spider-plots resuming how each 
component of the SF36v2 in SLE patients suffering with NDNE varies according to the presence of 
(B) active MS symptoms classified as MS-BILAG ≥ C and (C) US erosions. BP, bodily pain; GH, 
general health; MH, mental health; PF, physical functioning; RE, role emotional RF, role physical; 
SF, social functioning; VT, vitality. NDNE, non-deforming non-erosive. 
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